The Factors Influencing the Growth of SMEs in the EU Pharmaceutical Industry: An Empirical Analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28120%2F23%3A63561958" target="_blank" >RIV/70883521:28120/23:63561958 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The Factors Influencing the Growth of SMEs in the EU Pharmaceutical Industry: An Empirical Analysis

Popis výsledku v původním jazyce

Abstract SMEs are the economic backbone of Europe. In pharma companies, SMEs are the engines of innovation, playing a critical role in the creation of novel medications for patients. However, in reality, the scenario is not so favourable, and the objective of this research is to identify potential factors of negative growth in the pharmaceutical industry. The study used secondary data from the EU Industrial R&amp;D Investment Scoreboard in 2015 and 2020 to apply a multiple linear regression model, with the dependent variable being operating profit. The results are very interesting, for example, the nest sale has positive and operating profit has negative coefficients throughout the years, implying that operating expenses, costs of goods sold, and day-to-day costs are higher than sales revenue in most cases. In the model, we get that R&amp;D expenditure is having a positive relationship in 2015 but an insignificant probability value; however, it is negative and highly significant in 2020. Likewise, R&amp;D expenditures, the capital expenditure also does not go through identical patterns in these two periods. Therefore, further studies are required to go through several years to generalize an exact relationship among the variables.

Název v anglickém jazyce

The Factors Influencing the Growth of SMEs in the EU Pharmaceutical Industry: An Empirical Analysis

Popis výsledku anglicky

Abstract SMEs are the economic backbone of Europe. In pharma companies, SMEs are the engines of innovation, playing a critical role in the creation of novel medications for patients. However, in reality, the scenario is not so favourable, and the objective of this research is to identify potential factors of negative growth in the pharmaceutical industry. The study used secondary data from the EU Industrial R&amp;D Investment Scoreboard in 2015 and 2020 to apply a multiple linear regression model, with the dependent variable being operating profit. The results are very interesting, for example, the nest sale has positive and operating profit has negative coefficients throughout the years, implying that operating expenses, costs of goods sold, and day-to-day costs are higher than sales revenue in most cases. In the model, we get that R&amp;D expenditure is having a positive relationship in 2015 but an insignificant probability value; however, it is negative and highly significant in 2020. Likewise, R&amp;D expenditures, the capital expenditure also does not go through identical patterns in these two periods. Therefore, further studies are required to go through several years to generalize an exact relationship among the variables.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50204 - Business and management

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Proceedings IFKAD: Managing Knowledge for Sustainability

ISBN

978-88-96687-16-1

ISSN

2280-787X

e-ISSN

—

Počet stran výsledku

18

Strana od-do

303-318

Název nakladatele

Arts for Business Institute

Místo vydání

Matera

Místo konání akce

Matera

Datum konání akce

7. 6. 2023

Typ akce podle státní příslušnosti

EUR - Evropská akce

Kód UT WoS článku

—